GALT

Business Context and Reporting Period

Company: Galectin Therapeutics Inc. (GALT)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: A clinical-stage biopharmaceutical company developing therapies for fibrotic diseases and cancer, primarily focusing on belapectin (GR-MD-02), a galectin-3 inhibitor. The company has no product revenue and operates at a loss.

Key Financial Metrics

Note: The significant increase in current liabilities in 2026 is primarily due to the reclassification of long-term convertible notes and lines of credit to current liabilities following maturity date extensions to June 30, 2027.

Material Changes vs. Prior Period

• Reduced Operating Loss: Net loss decreased by approximately $3.0 million (17.5%) year-over-year, driven largely by a 55% reduction in R&D expenses following the completion of the NAVIGATE clinical trial in the prior year.
• Increased G&A Expenses: General and administrative expenses rose by 33% ($917,000) due primarily to increased non-cash stock-based compensation.
• Derivative Liability Volatility: The change in fair value of derivative liabilities resulted in a non-cash expense of $2.17 million for the six months ended June 30, 2026, compared to $1.12 million in the prior period.
• Debt Structure: While total debt obligations remain high, the company extended the maturity of all related-party convertible notes and lines of credit to June 30, 2027, reclassifying them as current liabilities on the balance sheet.

Outlook, Risks, and Management Commentary

• Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern for 12 months from the issuance date. Cash on hand ($13.3 million) plus available credit ($10 million) is projected to fund operations only through June 2027.
• Clinical Progress: The company reached an agreement with the FDA on the primary endpoint and regulatory path for belapectin in MASH cirrhosis. A Phase 3 protocol is planned for filing in Q3 2026. The company is actively seeking strategic partnerships to fund this development.
• Subsequent Event (Debt Conversion): On July 31, 2026, the Chairman, Richard E. Uihlein, elected to convert $91.0 million in principal and $14.8 million in accrued interest from the convertible lines of credit into 34,376,167 shares of common stock. This transaction significantly reduced the company's debt burden post-period.
• Internal Control Weakness: The company disclosed a material weakness in internal controls related to the valuation of derivative liabilities associated with contingent interest on convertible notes.
• Risk Factors: Key risks include dependence on Mr. Uihlein for financing, the need for additional capital to fund the Phase 3 trial, and the uncertainty of clinical trial outcomes.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $13.3 million cash balance and the $10 million undrawn line of credit to fund operations through June 2027 without further dilution or debt.
• Debt Conversion Impact: Confirm the final share count and dilution impact resulting from the July 31, 2026, conversion of $105.8 million in debt to equity by the Chairman.
• Phase 3 Funding: Assess the likelihood and terms of securing a strategic partner or new financing to fund the planned Phase 3 trial filing in Q3 2026.
• Derivative Valuation: Review the remediation plan for the material weakness in internal controls regarding derivative liability valuations.
• Preferred Stock Obligations: Monitor the status of Series A and Series C preferred stock dividends and conversion rights.